MyoKardia

M&A landscape is tilting away from late-stage buys and toward a platform strategy: analysts
M&A landscape is tilting away from late-stage buys and toward a platform strategy: analysts
Fierce Pharma
M&A
Accenture
Bristol Myers Squibb
MyoKardia
Flag link:
ACC 2022 – Bristol's rare hit could justify Myokardia
ACC 2022 – Bristol's rare hit could justify Myokardia
EP Vantage
ACC
Bristol Myers Squibb
MyoKardia
hypertrophic cardiomyopathy
mavacamten
Flag link:
BMS builds case for mavacamten label ahead of FDA decision
BMS builds case for mavacamten label ahead of FDA decision
Pharmaforum
Bristol Myers Squibb
mavacamten
obtructive hypertrophic cardiomyopathy
MyoKardia
FDA
Flag link:
A couple months ahead of its PDUFA data, Bristol Myers rolls out long-term data for mavacamten
A couple months ahead of its PDUFA data, Bristol Myers rolls out long-term data for mavacamten
Endpoints
Bristol Myers Squibb
FDA
mavacamten
MyoKardia
Flag link:
The top 10 largest biopharma M&A deals in 2020
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Flag link:
Astrazeneca shows megamergers were still possible in 2020
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Flag link:
Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia
Bristol Myers Squibb Closes $13.1 Billion Acquisition of MyoKardia
Motley Fool
Bristol-Myers Squibb
MyoKardia
M&A
Flag link:
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
[video+transcript]Here's What's Behind Bristol Myers Squibb's Huge Acquisitions
Motley Fool
Bristol-Myers Squibb
M&A
Celgene
MyoKardia
Flag link:
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
BioPharma Dive
M&A
cardiology
Bristol-Myers Squibb
MyoKardia
Novartis
The Medicines Company
Flag link:
Here's Why Bristol Myers Offered MyoKardia $13.1 Billion
Here's Why Bristol Myers Offered MyoKardia $13.1 Billion
Motley Fool
M&A
MyoKardia
Bristol-Myers Squibb
Flag link:
Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for the heart
Bristol Myers to buy MyoKardia in $13B bet on targeted drugs for the heart
BioPharma Dive
Bristol-Myers Squibb
M&A
MyoKardia
genetic heart disease
Flag link:
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
MyoKardia’s Heart Drug Shines in Phase 3, FDA Filing Planned for 2021
Xconomy
MyoKardia
clinical trials
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
Myokardia at inflection point as heart drug readout nears
Myokardia at inflection point as heart drug readout nears
BioPharma Dive
MyoKardia
clinical trials
heart disease
mavacamten
Flag link:
Safety qualms in MyoKardia mid-stage study cause investors to pause
Safety qualms in MyoKardia mid-stage study cause investors to pause
Endpoints
MyoKardia
obstructive hypertrophic cardiomyopathy
clinical trials
mavacamten
Flag link:
MyoKardia cuts all ties to Sanofi
MyoKardia cuts all ties to Sanofi
Biopharma Dive
MyoKardia
MYK-224
Sanofi
obstructive hypertrophic cardiomyopathy
mavacamten
Flag link:
MyoKardia raises $251.2M in follow-on
MyoKardia raises $251.2M in follow-on
BioCentury
MyoKardia
mavacamten
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Yahoo/Benzinga
IPOs
biotech
JNJ
Janssen
esketamine
Shockwave Medical
earnings
Sensen Bio
MyoKardia
Flag link:
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Sanofi walks away from MyoKardia heart drug partnership, long before key data readout
Endpoints
Sanofi
MyoKardia
mavacamten
obstructive hypertrophic cardiomyopathy
Flag link:
MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring
MyoKardia Heart Drug Boosts Blood Flow, Sends Shares Soaring
Xconomy
MyoKardia
hypertrophic cardiomyopathy
mavacamten
Flag link:
FierceBiotech's 2015 Fierce 15
FierceBiotech's 2015 Fierce 15
Fierce Biotech
Alector
Arvinas
Cell Medica
CRISPR Therapeutics
Denali Therapeutics
Intellia Therapeutics
MyoKardia
NGM Biopharmaceuticals
Padlock Therapeutics
Revolution Medicines SQZ Biotech
Surface Oncology
Syros Pharmaceuticals
Unum Therapeutics
Yumanity Therapeutics
Flag link:

Pages